Research perspectives in inherited lymphatic disease: An update

Annals of the New York Academy of Sciences

Volumn 1131, Issue , 2008, Pages 134-139

  Ferrell, Robert E ^a   Finegold, David N ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

FOXC2; Lymphangiogenesis; Lymphedema; Milroy's disease

Indexed keywords

AAGENAES SYNDROME; CONFERENCE PAPER; DISEASE MODEL; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; HENNEKAM LYMPHANGIECTASIS LYMPHEDEMA; HUMAN; HYPOTRICHOSIS LYMPHEDEMA TELANGIECTASIA SYNDROME; LYMPHATIC SYSTEM DISEASE; LYMPHEDEMA; LYMPHEDEMA CHOLESTASIS; MILROY DISEASE; NONHUMAN; NOONAN SYNDROME; PHENOTYPE; PTOSIS; YELLOW NAIL SYNDROME;

EID: 44449085797     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1413.012     Document Type: Conference Paper

References (39)

1. Cueni, L.N. & M. Detmar. 2006. New insights into the molecular control of the lymphatic vascular system and its role in disease. J. Invest. Dermatol. 126 : 2167 2177.
2. Adams, R.H. & K. Alitalo. 2007. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. 8 : 464 478.
3. Makinen, T., C. Norrmen & P.V. Petrova. 2007. Molecular mechanisms of lymphatic vascular development. Mol. Life Sci. e-pub ahead of publication.
4. Carver, C., G. Brice, S. Mansour, et al. 2007. Three children with Milroy disease and de novo mutations in VEGFR3. Clin. Genet. 71 : 187 189.
5. Karkkainen, M.J., A. Saaristo, L. Jussila, et al. 2001. A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. USA 98 : 12677 12682.
6. Saaristo, A., T. Veikkola, T. Tammela, et al. 2002. Lymphangiogenic gene therapy with minimal blood vascular side effects. J. Exp. Med. 196 : 719 730.
7. Yoon, Y., T. Murayama, E. Gravereaux, et al. 2003. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J. Clin. Invest. 111 : 717 725.
8. Kerjaschki, D., N. Huttary, I. Raab, et al. 2006. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nature Med. 12 : 230 234.
9. Saaristo, A., T. Tammela, A. Farkkila, et al. 2006. Vascular endothelial growth factor-C accelerates diabetic wound healing. Am. J. Pathol. 169 : 1080 1087.
10. Hu, Y., I. Rajantie, K. Pajusola, et al. 2005. Vascular endothelial growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Can. Res. 65 : 4739 4746.
11. Roberts, N., B. Kloos, M. Cassella, et al. 2006. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 66 : 2650 2657.
12. Iida, K., H. Koseki, H. Kakinuma, et al. 1997. Essentials roles of the winged helix transcription factor MFH-1 in aortic arch patterning and skeletogenesis. Development 124 : 4627 4638.
13. Winnier, G.E., L. Hargett & B.L.M. Hogan. 1997. The winged helix transcription factor MFH1 is required for proliferation and patterning of paraxial mesoderm in the mouse embryo. Gene Dev. 11 : 926 940.
14. Winnier, G.E., T. Kume, K. Deng, et al. 1999. Roles for the winged helix transcription factors MF1 and MFH1 in cardiovascular development revealed by nonallelic noncomplementation of null alleles. Dev. Biol. 213 : 418 431.
15. Kriederman, B.M., T.L. Myloyde, M.H. Witte, et al. 2003. FOXC2 haploinsufficient mice are a model for human autosomal dominant lymphedema-distichiasis syndrome. Hum. Mol. Genet. 12 : 1179 1185.
16. Petrova, T.V., T. Karpanen, C. Norrmen, et al. 2004. Defective values and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema-distichiasis. Nat. Med. 10 : 974 981.
17. Dagenais, S.L., R.L. Hartsough, R.P. Erickson, et al. 2004. FOXC2 is expressed in developing lymphatic vessels and other tissues with lymphedema-distichiasis syndrome. Gene Expression Patterns 4 : 611 619.
18. Rosbotham, J.L., G.W. Brice, A.H. Child, et al. 2000. Distichiasis-lymphadema: clinical features, venous function and lymphoscintigraphy. Br. J. Dermatol. 142 : 148 152.
19. Brice, G., S. Mansour R. Bell, et al. 2002. Analysis of the phenotypic abnormalities in lymphedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16p24. J. Med. Genet. 79 : 478 483.
20. Ng, M.Y.M., T. Andrew, T.D. Spector, et al. 2004. Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy unselected sibling pairs. J. Med. Genet. 43 : 235 239.
21. Mellor, R.H., G. Brice, A.B.W. Stanton, et al. 2007. Mutations in FOXC2 are strongly associated with primary value failure in veins of the lower limb. Circulation 115 : 1912 1920.
22. Sholto-Douglas-Vernon, C., R. Bell, G. Brice, et al. 2005. Lymphedema-distichiasis and FOXC2: unreported mutations, de novo mutation estimate, families without coding mutations. Hum. Genet. 117 : 238 242.
23. Fang, J., S.L. Dagenais, R.P. Ericson, et al. 2000. Mutations in FOXC2 (MFH1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am. J. Hum. Genet. 67 : 1382 1388.
24. Cederberg, A., L.M. Gronning & B. Ahren. 2001. FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance. Cell 106 : 563 573.
25. Ridderstrole, M., M. Carlsson, M. Klannermark, et al. 2002. FOXC2 mRNA expression and a 5′-untranslated region polymorphism of the gene are associated with insulin resistance. Diabetes 51 : 3554 3560.
26. Harvey, N.L., R.S. Shrinivasan, M.E. Dillard, et al. 2005. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat. Genet. 37 : 1072 1081.
27. Finegold, D.N., M.A. Kimak, E.C. Lawrence, et al. 2001. Truncating mutation in FOXC2 causes multiple lymphedema syndromes. Hum. Mol. Genet. 10 : 1185 1189.
28. Hoque, S.R., S. Mansour, P.S. Mortimer, et al. 2007. Yellow nail syndrome: not a genetic disorder? Eleven new cases and a review of the literature. Br. J. Dermatol. 156 : 1230 1234.
29. Tartaglia, M., E.L. Mehler, R. Goldberg, et al. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29 : 465 468.
30. Schubbert, S., M. Zenker, S.L. Rowe, et al. 2006. Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 38 : 331 398.
31. Tartaglia, M., L.A. Pennacchio, C. Zhao, et al. 2007. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat. Genet. 39 : 75 79.
32. Roberts, A.E., T. Araki, K.D. Swanson, et al. 2007. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat. Genet. 39 : 70 74.
33. Podgrabinska, S., P. Braun, P. Velasco, et al., 2003. Molecular characterization of lymphatic endothelial cells. Proc. Natl. Acad. Sci. USA 99 : 16069 16074.
34. Hirakawa, S., Y.W. Hong, N. Harvey, et al. 2003. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am. J. Pathol. 162 : 575 586.
35. Bull, L.N., E. Roche, E.J. Song, et al. 2002. Mapping of the locus for cholestasis- lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am. J. Hum. Genet. 67 : 994 999.
36. Fruhwirth, M., A.R. Janecke, T. Muller et al. 2003. Evidence for genetic heterogeneity in lymphedema-distichiasis syndrome. J. Pediatr. 142 : 441 447.
37. Irrthum, A., K. Devriendt, D. Chitayat, et al., 2003. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am. J. Hum. Genet. 72 : 1470 1478.
38. Pennisi, D., J. Gardner, D. Chambers, et al. 2000. Mutations in SOX18 underlie cardiovascular and hair follicle defects in ragged mice. Nat. Genet. 24 : 434 437.
39. James, K., B. Hosbing, J. Gardner, et al. 2003. SOX18 mutations in the ragged mouse alleles ragged like and opossum. Genesis 36 : 1 6.